325% rally in five years! Multibagger pharma stock in focus; here's why

In the second half of FY25 (H2FY25), Sudarshan Pharma Industries Limited (SPIL) reported a 19% rise in net sales to ₹277 crore and a 43% increase in net profit to ₹7 crore compared to H2FY24.

Markets